These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22315364)

  • 1. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.
    Thomas JA; Gerber L; Bañez LL; Moreira DM; Rittmaster RS; Andriole GL; Freedland SJ
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):576-81. PubMed ID: 22315364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
    Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
    Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and prostate cancer risk in the REDUCE trial.
    Wu C; Moreira DM; Gerber L; Rittmaster RS; Andriole GL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):326-31. PubMed ID: 21709690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
    Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
    Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of coronary artery disease and prostate-specific antigen relationship in men.
    Satiroglu O; Bostan M; Uzun H; Cetin M; Bozkurt E
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2078-81. PubMed ID: 23280022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40!
    Börgermann C; vom Dorp F; Swoboda A; Ketteniss O; Becker M; Rübben H
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1190-5. PubMed ID: 21447776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and prostate enlargement in men with localized prostate cancer.
    Kopp RP; Han M; Partin AW; Humphreys E; Freedland SJ; Parsons JK
    BJU Int; 2011 Dec; 108(11):1750-5. PubMed ID: 21736693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.